Avidity Biosciences (RNA) Competitors

Genmab A/S (NASDAQ:GMAB) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Which has more volatility and risk, GMAB or RNA?

Genmab A/S has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Do insiders & institutionals hold more shares of GMAB or RNA?

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts recommend GMAB or RNA?

Genmab A/S currently has a consensus price target of $37.80, suggesting a potential upside of 61.54%. Avidity Biosciences has a consensus price target of $66.35, suggesting a potential upside of 82.94%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Avidity Biosciences	0 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.06

Is GMAB or RNA more profitable?

Genmab A/S has a net margin of 35.11% compared to Avidity Biosciences' net margin of -4,136.00%. Genmab A/S's return on equity of 18.08% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	35.11%	18.08%	14.52%
Avidity Biosciences	-4,136.00%	-26.96%	-24.57%

Which has better earnings & valuation, GMAB or RNA?

Genmab A/S has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.81	$1.14B	$1.76	13.30
Avidity Biosciences	$10.90M	401.03	-$322.30M	-$3.00	-12.09

Does the media prefer GMAB or RNA?

In the previous week, Avidity Biosciences had 1 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Avidity Biosciences and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.27 beat Avidity Biosciences' score of 0.89 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Avidity Biosciences on 10 of the 16 factors compared between the two stocks.